Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

The renowned global provider of sample and assay technologies has a market capitalization of $10.30 billion. QGEN’s earnings surpassed estimates in three of the trailing four quarters and missed on ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Minnesota Attorney General Keith Ellison says he will announce "a major development in his litigation against the three ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly ...

Eli Lilly’s CEO Dave Ricks told Bloomberg News earlier this ... However, the selection of Ozempic and Wegovy for the second round of bargaining could prompt insurers in the commercial market to push ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival ...

Eli Lilly’s CEO Dave Ricks told Bloomberg News ... for the second round of bargaining could prompt insurers in the commercial market to push for better deals for their policyholders.

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...